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Background: Streptococcus pneumoniae serotypes distribution in community-acquired pneumonia (CAP)
requiring hospitalization in adults after introduction of PCV13 in children is not well known. Our aim
was to evaluate the distribution of serotypes in pneumococcal pneumonia according to risk factors
and comorbidity conditions after the introduction of PCV13 in children in 2010.
Methods: A prospective study from 2011 to 2014 was performed in immunocompetent adults hospital-
ized with CAP in 3 Spanish hospitals. Microbiological confirmation was obtained using a serotype specific
urinary antigen detection test (UAD test), Binax Now and conventional cultures.
Results: 1258 adults were enrolled and pneumococcal pneumonia (invasive disease in 17.7%) was con-
firmed in 368 (29.3%) and 17.6% of the any-cause CAP were caused by PVC13 serotypes (3.5% PCV7 ser-
otypes). Around 60% of pneumococcal CAP were caused by PCV13 serotypes (74.6% in invasive episodes
vs 57.4% in non-invasive ones). The most prevalent serotypes in invasive disease were 1, 3, 7F, 19A and
14. No significant differences were observed in the distribution of PCV13 serotypes across the study peri-
ods. Regarding comorbidity, the rate of PCV13 serotypes was similar among them, and it was slightly
higher in those with no underlying conditions.
Conclusions: Serotypes included in PCV13 caused a significant proportion of CAP in adults with underly-
ing conditions and in healthy adults, with no significant changes in cases due to PCV7 or PCV13 from
2011 to 2014, suggesting an insufficient indirect protection from childhood vaccination. Strategies for
implementing pneumococcal vaccination of adults are encouraged to reduce the incidence of pneumo-
coccal episodes.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Pneumococcal disease in adults, including community-acquired
pneumonia (CAP) and invasive pneumococcal disease (IPD), is a
global health problem, mainly affecting individuals with chronic
diseases such as COPD, diabetes mellitus and heart disease. Theincreased risk for pneumococcal pneumonia is present all year
around [1] and the total disease burden comes mainly from non-
invasive episodes, because IPD represents only a fraction [2].
There are more than 90 different pneumococcal serotypes
showing diverse clinical expression, invasiveness and outcome.
The distribution of circulating pneumococcal serotypes depends
on several factors including the presence of underlying diseases,
contact with children, and vaccination status, and changes over
time making continuous monitoring necessary. Vaccinating chil-
dren with the 7-valent pneumococcal conjugate vaccine (PCV7)
achieved a reduction in adult invasive pneumococcal disease
caused by serotypes included in the vaccine and a drift in othersvel uri-
2 R. Menéndez et al. / Vaccine xxx (2017) xxx–xxx[3]. The impact that the introduction of the 13-valent pneumococ-
cal conjugate vaccine (PCV13) in 2010 for healthy children has had
on the burden of pneumococcal pneumonia in adults due to PCV13
serotypes, particularly CAP without bacteraemia and CAP in high
risk groups, is not well known [4]. Moreover, its indirect effect
on pneumococcal pneumonia in adults is uncertain, although some
impact has been found in the UK, where infant PCV coverage is
around 95% [5]. In adults aged 65 and older, PCV13 has demon-
strated efficacy in the prevention of pneumococcal pneumonia
and invasive pneumococcal disease [6].
We hypothesized that the distribution of pneumococcal sero-
types in adults, in both invasive and non-invasive pneumonia,
might have changed after the introduction of PCV13 for children
[7] and that this distribution may vary depending on the patients’
comorbidity and/or risk factors [8]. Given the fact that hospitaliza-
tion for pneumonia is not decreasing [9] and that S. pneumoniae is
the main causative microorganism, updated information will be a
key factor for implementing effective strategies to decrease the
incidence of CAP.
The aim of our study was to evaluate the burden of pneumococ-
cal pneumonia in adults with regard to the distribution of PCV13
serotypes using the new UAD test in urine according to comorbidi-
ties and/or risk habits in immunocompetent patients after the
introduction of PCV13 in children.
2. Patients and methods
A prospective multicentre epidemiological study was per-
formed in three tertiary-care teaching hospitals from the National
Spanish Health System, covering a population around 900.000
inhabitants (Hospital La Fe 285.000, Hospital Clinic 300.000, Hospi-
tal Galdakao 310.000) in immunocompetent adults aged
18 years, hospitalized during November 2011 to November
2014. Patients were considered to have CAP when they presented
a new radiologic infiltrate accompanied by acute signs and symp-
toms suggestive of lower respiratory tract infection. Exclusion cri-
teria were previous hospitalization that lasted at least 48 h within
the 2 weeks prior to the current admission, active pulmonary
tuberculosis, sickle cell anemia, immunosuppression (HIV infec-
tion/AIDS or immune suppression by any other cause), current can-
cer treatment or cancer treatment during the year prior to the
study, and functional or anatomic asplenia. The ethics committee
at each hospital approved the study and patients signed written
informed consents.
Data on age, gender, smoking, alcohol consumption, prior
antimicrobial treatment, comorbidity conditions (chronic obstruc-
tive pulmonary disease, asthma, diabetes mellitus, chronic heart
failure, chronic kidney failure, chronic liver disease, cerebrovascu-
lar disease, cancer), history of previous pneumonia, of previous
hospitalization and of flu and pneumococcal vaccination were
recorded for each patient. Initial severity was evaluated using the
Pneumonia Severity Index (PSI) and the CURB-65 score. In the
chest X-ray, we recorded the extension of infiltrate and the pres-
ence of pleural effusion.
During hospitalization the appearance of new complications,
episodes requiring mechanical ventilation, treatment failure,
admission into the intensive care unit (ICU), length of stay, and
outcome were recorded.
2.1. Microbiological results
Microbiological studies were performed at each participating
hospital according to standard clinical practice and based on clin-
ical judgment of the attending physician. Cultures were done on
available samples from blood (n: 844), pleural fluid (n: 93), or
other body fluids, sterile under normal conditions, and/or goodPlease cite this article in press as: Menéndez R et al. The burden of PCV13 sero
nary antigen detection test. CAPA study. Vaccine (2017), http://dx.doi.org/10.1quality sputum (<10 epithelial cells and >25 leukocytes per field;
magnification x 100) (n: 444). Urinary antigen tests performed
were Binax Now S. pneumoniae Urinary Antigen Test (n:1190)
and Binax Now L. pneumophila Urinary Antigen Test (n:1190).
Other tests were performed to 322 patients, like PCR for viruses
in 244 patients and serological studies for the detection of antibod-
ies to Chlamydophila pneumoniae, Mycoplasma pneumoniae, Coxiella
burnetii and L. pneumophila.
Urine samples obtained were processed and stored between
20 C and 70 C at each participating hospital in all patients
(n: 1258) until they were sent to the sponsor’s central laboratory
in Pearl River, New York, USA to perform the serotype specific uri-
nary antigen detection (UAD) test. This test consists of an
immunochromatographic membrane assay using monoclonal anti-
bodies of the serotype-specific capsular polysaccharide. The assay
detects the thirteen S. pneumoniae serotypes included in PCV13
(serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F)
and has a sensitivity and specificity of 98% and 100%, respectively
[10].
Pneumococcal isolates were identified by the optochin-
susceptibility and bile solubility tests and they were stored frozen
in skimmed milk at 40 C or lower until delivery to the central
laboratory [Microbiology Department, University Hospital Donos-
tia, Donostia-San Sebastián (Spain)]. Serotyping was performed
by multiplex-PCR [11] and confirmed by the Quellung reaction
using polyclonal antisera (Statem Serum Institute, Copenhagen,
Denmark), antibiotic susceptibility testing (broth microdilution,
CLSI guidelines) and genotyping (MLST) were performed by this
central laboratory on all isolates sent.
2.2. Definitions
Pneumococcal CAP etiology was considered present if any
microbiological test was positive (Binax Now test, UAD test, blood
culture, pleural culture and sputum culture). Invasive disease was
confirmed if S. pneumoniae was isolated in blood and/or pleura
fluid. Non-invasive disease was defined as confirmed pneumococ-
cal CAP (by UAD test or Binax Now test) for which blood and/or
pleura fluid culture results were negative. Pneumococcal serotypes
were categorized as follows: 4, 6B, 9V, 14, 18C, 19F and 23F as
‘‘PCV7” serotypes; 1, 3, 5, 6A, 7F, 19A plus PCV7 included serotypes
as ‘‘PCV13” serotypes.
Complicated CAP at presentation was considered if one of the
following was present: multilobar infiltrates, bacteraemia, pleural
effusion or empyema, respiratory failure, severe sepsis or septic
shock. Severe sepsis was considered present in cases of any organ
failure other than respiratory failure. Treatment failure was consid-
ered according to Spanish guidelines [12]. Clinical stability with
modified Halm criteria [13] was considered achieved when vital
signs of a patient were stable for a 24 h period (i.e. heart rate
<100 beats per minute; respiratory rate <24 breaths per minute;
axillary temperature <37.2 C; systolic blood pressure >90 mmHg;
oxygen saturation >90%; good level of consciousness; tolerance to
oral via.
2.3. Statistical analyses
Data analysis was performed using SPSS 19.0 software and EPI-
DAT 3.0. For comparisons of independent samples, the Pearson chi-
squared test (or the exact Fisher test for 2  2 tables or likelihood
ratio for mxn tables, if necessary) for qualitative variables and Stu-
dent’s t test, single factor ANOVA or its non-parametric equivalent
U-Mann-Mann, H-Kruskal_Wallis for quantitative variables were
used. The assumptions of normality and homoscedasticity of the
variables were studied for use of parametric tests. The pneumococ-
cal CAP group was stratified as invasive and non-invasive CAP.types in hospitalized pneumococcal pneumonia in Spain using a novel uri-
016/j.vaccine.2017.08.007
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A total of 1258 patients were recruited from November 2011 to
November 2014 (Table 1). Microbiological aetiology was found in
573 patients (45.5%): 368 (29.3%) S. pneumoniae, 24 (1.9%) L. pneu-
mophila, 19 (1.5%) Staphylococcus aureus, 21 (1.7%) Influenza virus,
12 (1.0%) other virus, and 129 (10.3%) others microorganisms
(Fig. 1). Pneumococcal CAP was diagnosed in 368 patients. No sig-
nificant changes were observed in the percentage of all-cause CAP
due to S. pneumoniae during the three years of the study (Table 2).
Of the 368 cases of pneumococcal CAP, 65 (17.7%) were invasive
and 303 (82.3%) were non-invasive. Pneumococcal CAP cases
showed a higher proportion of asthmatic patients (11.4% vs 7.8%;
p < 0.05) and alcohol abuse (4.9% vs 2.4%; p < 0.05), higher PSI
(45.8% vs 39% for PSI risk class IV-V; p < 0.05) and CURB65 (1.49
vs 1.26; p < 0.001) punctuations and more ICU admission (13.4%
vs 9.4%; p < 0.05).3.1. Serotype distribution
Serotype distribution showed that 17.6% of all-cause CAP was
caused by serotypes included in PCV13 without significant differ-
ences throughout the study period. Pneumococcal pneumonia
was caused in 60% of the cases by PCV13 serotypes and it was
greater in invasive diseases (74.6%) with no significant differences
during the three years of the study (Table 2). The percentage of
cases due to PCV7 serotypes was 12% for pneumococcal pneumo-
nia and 9.5% in invasive episodes. The distribution of PCV13 sero-
types identified in invasive pneumococcal pneumonia and in
non-invasive pneumonia is shown in Fig. 2. Although invasive
cases were caused more frequently by PCV13 serotypes than were
in non-invasive cases (74.6% vs 57.4%; p < 0.05), no significant dif-
ferences were observed for individual serotypes except for sero-Table 1
Characteristics of study population in the whole cohort and in pneumococcal CAP.
Any-cause CAP Pneumococcal CAP
(n = 1258) (n = 368)
N (%) N (%)
Demographic data
Age [mean(SD)] 67.41 (17.90) 67.64 (17.82)
Gender (male) 763 (60.7%) 216 (58.7%)
Spanish nationality 1211 (96.3%) 352 (95.7%)
Underlying conditions (1)
No underlying condition 155 (12.3%) 54 (14.7%)
COPD 232 (18.4%) 73 (19.8%)
Chronic heart failure 159 (12.6%) 37 (10.1%)
Diabetes mellitus 301 (23.9%) 77 (20.9%)
Chronic liver disease 42 (3.3%) 11 (3.0%)
Chronic renal failure 117 (9.3%) 33 (9.0%)
Stroke 101 (8.0%) 27 (7.3%)
Asthma 111 (8.8%) 42 (11.4%)
Cured neoplasia 112 (8.9%) 37 (10.1%)
Previous hospitalization 27 (2.1%) 8 (2.2%)
Previous pneumonia 206 (16.4%) 63 (17.1%)
Toxic habits
Smokinga 201 (16.0%) 59 (16.0%)
Alcoholismb 39 (3.1%) 18 (4.9%)
Vaccination history
Flu vaccine 587 (46.7%) 161 (43.8%)
Pneumococcal vaccine 99 (7.9%) 22 (6.0%)
PSI score
I–II 403 (32.2%) 120 (32.7%)
III 336 (26.8%) 79 (21.5%)
IV 421 (33.6%) 131 (35.7%)
V 93 (7.4%) 37 (10.1%)
a Smoking: smokers of 10 cigarettes per day within the previous year or quit-
ting smoking less than 6 months before.
b Alcoholism: intake 80 gr per day during at least the previous year.
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(representing at least 5%) identified in the invasive cases were 1
(27%), 3 (16%), 7F (14.3%), 14 (7.9%), 19A (7.9%) and 8 (6.3%). For
the non-invasive pneumococcal pneumonia cases, the most fre-
quent serotypes were 3 (23.1%), 7F (6.9%) 19A (6.9%) and 14
(5.3%). No significant differences were found within each hospital
for all-cause CAP or pneumococcal pneumonia cases due to PCV7
or PCV13 serotypes during the study period.
The distribution of PCV13 serotypes according to initial presen-
tation of pneumococcal pneumonia cases is depicted in Supple-
mental file 1. Serotype 3 was the most frequent serotype in all
the variables related to initial severity except for cases complicated
with bacteraemia which was serotype 1, with empyema which
were serotypes 3 and 1 and, for cases complicated with severe sep-
sis which was serotype 7F.
Regarding serotype distribution according to underlying condi-
tions, serotypes included in PCV13 accounted for 72.7% of cases in
patients with no underlying conditions, for 69.3% (70/101) in
patients with 1 underlying condition, and for 52.1% (110/211) in
patients with at least two underlying conditions. Table 3 shows
serotypes distribution according to the most prevalent underlying
conditions in CAP and pneumococcal CAP episodes. In those with
no underlying conditions there was a significantly higher total bur-
den of PCV13 serotypes compared to patients with at least one
underlying condition (72.2% vs 57.7%; p = 0.032).3.2. Complications, LOS and outcome
During hospitalization, 358 patients presented new complica-
tions. Death occurred in 35 patients (2.8%), most of them (32 cases)
during hospitalization. PCV13 serotypes distribution according to
complications, length of stay and mortality are shown in Supple-
mental file 2. Serotype 3 was the most frequent in patients pre-
senting complications during hospitalization, with the exception
of the cases complicated with sepsis where 3 and 14 were equally
frequent serotypes. Serotype 3 was also the most frequent serotype
in patients requiring invasive mechanical ventilation, in cases with
a length of stay at hospital or in the ICU longer than 7 days and, in
cases taking more than 4 days to become clinically stable.4. Discussion
The most outstanding findings of our study are 1. More than
60% of pneumococcal CAP cases in immunocompetent adults were
caused by PCV13 serotypes (74.6% in invasive episodes and 57.4%
in non-invasive episodes) showing no significant changes from
2011 to 2014. 2. The most frequent serotypes in pneumococcal
CAP were 3, 1, 7F and 19A. 3. The percentage of CAP caused by
PCV13 serotypes varied slightly according to the presence of
underlying conditions (from 49.2% in previous CAP to 64.9% in dia-
betics) and was higher in patients without comorbidities and/or
risk factors.
In our cohort, 29.3% of patients had pneumococcal CAP of whom
17.7% had invasive episodes. Regarding underlying conditions,
85.3% of our patients with pneumococcal CAP had at least one
comorbidity and/or risk habit. Some chronic conditions, such as
respiratory disease, current smoking, heart disease or diabetes,
increase the risk for pneumococcal pneumonia between 3 and 9-
fold [1]. That increase in risk is accumulative in patients with mul-
tiple risk factors mainly in those with 3 or more chronic conditions
[14,15].
Regarding circulating serotypes, there is much more informa-
tion in IPD [16–18] than on non-invasive disease despite the fact
that pneumococcal CAP is responsible for the major burden of
pneumococcal disease. Prior to PCV13 introduction, data on seculartypes in hospitalized pneumococcal pneumonia in Spain using a novel uri-
016/j.vaccine.2017.08.007
Fig. 1. Microbiological results of CAP (N = 1258) and pneumococcal CAP (N = 368). 2011–2014.
Table 2
Distribution of PCV7 and PCV13 vaccine serotypes in any-cause CAP and in invasivea and non-invasiveb pneumococcal CAP by study period.
Nov 2011–Nov 2012 Nov 2012–Nov 2013 Nov 2013 –Nov 2014 Total p-value
Disease N (%) N (%) N (%) N (%)
Any-cause CAP N = 431 N = 434 N = 393 N = 1258
PCV13 serotypes 77 (17.9) 85 (19.6) 59 (15.0) 221 (17.6) 0.217
PCV7 serotypes 13 (3.0) 18 (4.1) 13 (3.3) 44 (3.5) 0.649
Most prevalent serotypes 3 (25; 5.8%) 3 (32; 7.4%) 3 (23; 5.9%) 3 (80; 6.4%) 0.571
1 (13; 3.0%) 1 (12; 2.8%) 1 (6; 1.5%) 1 (31; 2.5%) 0.312
7F (11; 2.6%) 7F (10; 2.3%) 7F (9; 2.3%) 7F (30; 2.4%) 0.962
19A (8; 1.9%) 19A (12; 2.8%) 19A (6; 1.5%) 19A (26; 2.1%) 0.435
CAP due to S. pneumoniae 114 (26.5) 143 (32.9) 111(28.2) 368 (29.3) 0.097
PCV13 serotypes 77 (67.5) 85(59.4) 59(53.2) 221(60.1) 0.085
PCV7 serotypes 13(11.4) 18(12.6) 13(11.7) 44(12.0) 0.954
Invasive CAPa 19 (16.7) 31 (21.7) 15 (13.5) 65 (17.7) 0.225
PCV13 serotypes 13 (72.2) 25 (83.3) 9 (60.0) 47 (74.6) 0.309
PCV7 serotypes 0 (0.0) 6 (20.0) 0 (0.0) 6 (9.5) 0.008
Non-PCV13 serotypes 5 (26.3) 5 (16.1) 6 (40) 16 (24.6) 0.309
Most prevalent serotypes 1 (6; 31.5%) 1 (8; 25.8%) 1 (3; 20%) 1 (17; 26.1) 0.688
3 (2; 10.5%) 3 (5; 16.1%) 3 (3; 20%) 3 (10; 15.4%) 0.768
7F (4; 21%) 7F (3; 9.8%) 7F (2; 13.4%) 7F (9; 13.8%) 0.517
14 (0) 14 (5; 16.1%) 14 (0) 14 (5; 7.7%) 0.019
19A (1; 5.3%) 19A (3; 9.7%) 19A (1; 6.7%) 19A (5; 7.7%) 0.839
8 (1; 5.3%) 8 (2; 6.4%) 8 (1; 6.7%) 8 (4; 6.1%) 0.986
22F (1; 5.3%) 22F (1; 3.2%) 22F (1; 6.7%) 22F (3; 4.6%) 0.869
6C (2; 10.5%) 6C (0) 6C (0) 6C (2; 3.0%) 0.075
11A (0) 11A (1; 3.2%) 11A (1; 6.7%) 11A (2; 3.0%) 0.445
12F (0) 12F (0) 12F (2; 13.4%) 12F (2; 3.0%) 0.051
13 (1; 5.3%) 13 (1; 3.2%) 13 (0) 13 (2; 3.0%) 0.537
29 (0) 29 (0) 29 (1; 6.7%) 29 (1; 1.5%) 0.232
9V (0) 9V (1; 3.2%) 9V (0) 9V (1; 1.5) –
Non-invasive CAPb 95 (83.3) 112 (78.3) 96 (86.5) 303 (82.3) 0.225
PCV13 serotypes 64 (67.4) 60 (53.6) 50 (52.1) 174 (57.4) 0.057
PCV7 serotypes 13 (13.7) 12 (10.7) 13 (13.5) 38 (12.5) 0.759
Most prevalent serotypes 3 (23; 24.2%) 3 (27; 24.1%) 3 (20; 20.8%) 3 (70; 23.1%) 0.813
7F (7; 7.4%) 7F (7; 6.2%) 7F (7; 7.3%) 7F (21; 6.9%) 0.937
19A (7; 7.4%) 19A (9; 8.0%) 19A (5; 5.2%) 19A (21; 6.9%) 0.701
14 (6; 6.3%) 14 (5; 4.5%) 14 (5; 5.2%) 14 (16; 5.3%) 0.839
1 (7; 7.4%) 1 (4; 3.6%) 1 (3; 3.1%) 1 (14; 4.6%) 0.327
6A (6; 6.3%) 6A (1; 0.9%) 6A (2; 2.0%) 6A (9; 2.9%) 0.067
a Isolate of S. pneumoniae in blood and/or pleural fluid. Among 65 cases identified, 2 isolates not serotyped.
b Confirmed pneumococcal CAP (by UAD or Binax Now) for which blood and/or pleural fluid culture result were negative. Data of non-PCV13 serotypes causing invasive
CAP are included in italic font.
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Fig. 2. Distribution of PCV13 serotypes in pneumococcal pneumonia (n = 368) cases according to the presence of invasive disease.
Table 3
Serotype distribution according to presence of underlying conditions.a
Diabetes
mellitus
COPD Previous
CAP
Smoking Heart
failure
Chronic renal
failure
Asthma No underlying
conditions
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Any- cause CAP. 1258 301 (23.9) 232 (18.4) 206 (16.4) 201 (16.0) 159 (12.6) 117 (9.3) 111 (8.8) 155 (12.3)
PCV13 serotypes 50 (16.6) 37 (15.9) 31 (15.0) 37 (18.4) 20 (12.6) 20 (17.1) 22 (19.8) 39 (25.2)
PCV7 serotypes 6 (2.0) 9 (3.9) 7 (3.4) 5 (2.5) 8 (5.0) 3 (2.6) 3 (2.7) 5 (3.2)
Pneumococcal CAP 368 (29.3) 77 (25.6) 73 (31.5) 63 (30.6) 59 (29.4) 37 (23.3) 33 (28.2) 42 (37.8) 54 (34.8)
PCV13 serotypes 50 (64.9) 37 (50.7) 31 (49.2) 37 (62.7) 20 (54.1) 20 (60.6) 22 (52.4) 39 (72.2)
PCV7 serotypes 6 (7.8) 9 (12.3) 7 (11.1) 5 (8.5) 8 (21.6) 3 (9.1) 3 (7.1) 5 (9.3)
Invasive CAPb 11 (14.3) 4 (5.5) 4 (6.3) 16 (27.1) 6 (16.2) 6 (18.2) 8 (19.0) 12 (22.2)
65 (17.7)
PCV13 serotypes 9 (81.8) 3 (75.0) 3 (75.0) 10 (62.5) 3 (50.0) 5 (83.3) 7 (87.5) 12 (100.0)
PCV7 serotypes 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 2 (16.7)
Non-invasive CAPc 66 (85.7) 69 (94.5) 59 (93.7) 43 (72.9) 31 (83.8) 27 (81.8) 34 (81.0) 42 (77.8)
303 (82.3)
PCV13 serotypes 41 (62.1) 34 (49.3) 28 (47.5) 27 (62.8) 17 (54.8) 15 (55.6) 15 (44.1) 27 (64.3)
PCV7 serotypes 6 (9.1) 8 (11.6) 7 (11.9) 5 (11.6) 8 (25.8) 3 (11.1) 2 (5.9) 3 (7.1)
a Patients might have more than one underlying condition.
b Isolate of S. pneumoniae in blood and/or pleural fluid. Among 65 cases identified, 2 isolates not serotyped.
c Confirmed pneumococcal CAP (by UAD or Binax Now) for which blood and/or pleural fluid culture result were negative.
R. Menéndez et al. / Vaccine xxx (2017) xxx–xxx 5trend of pneumococci serotypes in Spain indicated that the per-
centage of PCV13 isolates among IPD cases showed an increasing
trend until 2001, reaching nearly 90%, followed by a decrease,
which was most prominent since 2010 when they accounted for
around 70% of the isolates. A decrease of 32.3% was found in the
percentage of PCV13 isolates from 2010 to 2013 [19].
We studied the burden of pneumococcal disease from PCV13
serotypes using a serotype specific urinary antigen detection test
(Pfizer UAD test) [10] in addition to conventional serotyping of
strains from blood or pleural fluid cultures. These tests achieve a
more accurate determination of pneumococci serotypes in non-Please cite this article in press as: Menéndez R et al. The burden of PCV13 sero
nary antigen detection test. CAPA study. Vaccine (2017), http://dx.doi.org/10.1invasive pneumonia [20–22] than can be achieved by serotyping
samples from lower respiratory tract. In fact, some serotypes might
be underestimated if only invasive disease is taken into account
and samples from the lower respiratory tract might confound col-
onization with infection.
Our findings showed that 13 years after introduction of PCV7/
PCV13 for children in our country, mainly with private funding
and with an estimated uptake of around 61% [23], 17.6% of CAP
was caused by PCV13 serotypes, and that 3.5% of CAP was caused
by PCV7 serotypes, indicating that a significant proportion of
adults continue to develop vaccine serotype CAP. In addition, thesetypes in hospitalized pneumococcal pneumonia in Spain using a novel uri-
016/j.vaccine.2017.08.007
6 R. Menéndez et al. / Vaccine xxx (2017) xxx–xxxresults also suggest that childhood immunization has not elimi-
nated the circulation of PCV7 serotypes. This finding is similar to
that of Sherwin et al. [21] in USA and Bewick et al. in UK [20], with
a higher infant uptake, pointing out the insufficient indirect protec-
tion from pneumococcal CAP in adults as a result of childhood
vaccination.
Serotype 3 was the most prevalent serotype in CAP accounting
for 21.7% of the cases, followed by far by serotypes 1, 7F and 19A.
Nevertheless, serotype 1 was the most prevalent (17 cases; 27%) in
invasive pneumococcal CAP, whereas serotype 3 was more fre-
quent (70 cases; 23%) in non-invasive pneumococcal CAP. Sero-
types 1 and 3 have been associated with complicated
pneumonia, specifically with empyema and necrotizing pneumo-
nia [24,25]. The different distribution of serotypes 1 and 3 in inva-
sive and non-invasive cases found in our study does not seem to be
explained by differences in nasopharyngeal carriage and patho-
genic potential. Serotype 1 is rarely identified in carriage but has
high pathogenic potential, whereas serotype 3 has low carriage
prevalence and high pathogenic potential [26]. On the other hand,
the high prevalence of PCV13 serotypes on pneumococcal CAP
found in our study, mainly for serotypes 3, 1, 7F and 19A, suggests
that indirect protection of adults against pneumococcal CAP is not
as evident as that observed against IPD [3,18] or against pneumo-
coccal CAP [5,26] in countries with well-established pneumococcal
vaccination programs for children using PCV7/PCV13. Neverthe-
less, we observed a non-significant decreasing trend in the per-
centage of non-invasive CAP cases due to PCV7/13 serotypes
throughout the study period. This decrease could be explained by
a possible early indirect effect of PCV13 infant vaccination, as pre-
viously reported [3,5]. However it should be taken into account
that a longer period of time and higher vaccine uptake is needed
for the herd effect to substantially decrease pneumococcal disease
at a population level [27].
We confirmed more invasive episodes in patients who smoked
(27%) followed by patientswith asthma, and chronic renal and heart
disease. Interestingly, therewere a considerable number of episodes
in patients without underlying conditions (22%). With regard to the
serotypes identified in invasive cases, we found that the percentage
of PCV13 serotypes ranged from 100% in those with no underlying
conditions to 75–85% in those with diabetes, COPD, chronic renal
disease and asthma. Ardanuy et al. [17] studied IPD episodes in
patients >65 years and found that PCV13 serotypes (19A, 3, 7F, 14
and 1) were the most prevalent, causing 59.3% of episodes.
The distribution of PCV13 serotypes in pneumococcal disease
related to comorbidity conditions and/or risk factors is quite
unknown although it has been suggested that different conditions
may predispose to different serotypes. The highest percentage of
PCV13 serotypes was found in diabetics (64.9%), smokers (62.7%),
and in patients with chronic renal disease, while it was lowest in
those with previous pneumonia (49.2%). Interestingly in those with
no underlying conditions the total burden of PCV13 serotypes was
the highest, and significantly higher than in patients with at least
one underlying condition. PCV7 serotypes showed higher percent-
ages in patients with heart disease or COPD. Except in asthmatic
patients, serotype 3 was the most prevalent, followed by 19A
and 7F. In COPD patients with exacerbations and pneumonia, ser-
otypes 10A, 11A, and 33F were found more frequently found in
sputum while 1, 3, 5 and 8 were more frequent in blood causing
bacteraemia [28].
The serotypes most frequently found in invasive episodes were
3, 1, 7F and 19A. Serotype 3 has been frequently associated with
complications such as empyema [29], septic shock [30] and respi-
ratory failure [31]. The different capacities of serotypes to adhere
to the respiratory epithelium due to the expression of different
adhesins has been found to be related to virulence [32]. In an ani-
mal model, it has been shown that the different capsular types pro-Please cite this article in press as: Menéndez R et al. The burden of PCV13 sero
nary antigen detection test. CAPA study. Vaccine (2017), http://dx.doi.org/10.1voke diverse inflammatory responses, with 14 and 23F among
those responsible for the most severe responses [33]. Nevertheless,
we found no significant differences in mortality [34] as it has been
reported that host factors have greater influence on outcomes [35].
This study has some limitations: 1) the CAP cases included were
only those admitted to hospital and thus, the characteristics and
distribution of serotypes in non-hospitalized patients is not
known; 2) incidence rates could not be calculated and thus, the
potential impact of childhood pneumococcal vaccination on pneu-
mococcal CAP is not well characterized; 3) only 65 invasive sam-
ples were sent to the central microbiology laboratory and thus,
invasive episodes may have been underestimated. Nevertheless,
the results of this study offer some insights and suggestions as to
the distribution of serotypes in pneumococcal CAP, and especially
in non-invasive pneumococcal CAP.
In summary, we found that pneumococcal serotypes included in
PCV13 cause a significant proportion of CAP in adults, but found no
significant changes in cases due to PCV7 or PCV13 serotypes from
2011 to 2014, suggesting an insufficient indirect protection from
pneumococcal vaccination of infants with PCV7/PCV13 during
the study period. That proportion varied slightly according to the
presence of underlying conditions and was higher in healthy
adults, suggesting that a high percentage of adults would benefit
from direct pneumococcal CAP protection. There is a need for
strategies to implement pneumococcal conjugate vaccination to
prevent pneumococcal pneumonia in adults in order to drastically
reduce the current burden of the disease and to continue monitor-
ing serotype distribution of non-invasive cases in the future.
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